Insurance denied Wegovy or Zepbound (October 2026): appeal within 180 days, and what else works

There are three, and the denial letter or a call to the number on your card tells you which. The drug is off the formulary, the plan wants a prior authorization it has not received or approved, or the plan excludes weight-management drugs altogether. The first two can be fixed with paperwork; the third is a plan-design decision that an appeal rarely reverses.

If you are on Medicare or Medicaid, skip route 2: savings cards generally exclude you (details under route 2). Medicare has its own path, covered further down.

Ask your prescriber's office to submit, or resubmit, the prior authorization with everything the plan's criteria list, then file an internal appeal if it is still denied. Cost: nothing but time. If it works, you pay your plan's copay, and route 2 can bring that to as little as $25 a month, about $7–10 per pound over a year. Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect

What the prescriber should send:

• Current BMI with height, weight and date. The labels cover a BMI of 30 or more, or 27 or more with at least one weight-related condition.
• Weight-related conditions, with diagnosis codes: hypertension, type 2 diabetes or prediabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease.
• Earlier weight-loss attempts: dates, programs, diets or medications tried and what happened. Many plans require three to six months of a documented lifestyle program before they approve.
• A letter of medical necessity that answers the plan's written criteria point by point. Ask the plan for the criteria document; you are entitled to see it.

Why a qualifying BMI can still be denied. Clearing the label's BMI is often not enough for the plan. The usual gaps are missing dated weight records (plans want weights with dates over time, not one reading) and no record of a medically supervised diet or exercise attempt, so ask the prescriber to send both.

Ask for a peer-to-peer review. After a prior authorization denial, your prescriber can ask the plan for a peer-to-peer review: a phone call with the plan's reviewing doctor about your case, in which the prescriber can answer the reviewer's questions directly. Whether it is the right step depends on the denial reason; process and clinic fees vary.

A different approved use can get around an exclusion. Wegovy is also FDA-approved to reduce cardiovascular risk in adults with established cardiovascular disease and excess weight, and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. If either fits you, a prior authorization under that indication is not a weight-loss claim. More on the two indications.

Deadlines. On most plans you have 180 days from the denial notice to file an internal appeal, and if the plan still says no you can ask for an independent external review (HealthCare.gov). The appeal letter builder at the top of this page drafts the appeal letter, a letter of medical necessity for your prescriber, the checklist and your deadlines. For a self-funded employer plan with a written exclusion, the more useful conversation is with HR or the benefits team before the next plan year.

Only partly. The as-little-as-$25 copay on the Zepbound and Wegovy savings cards needs commercial insurance that covers the drug, so it is what you stack on top of a won appeal, not a substitute for one. If your commercial plan does not cover the drug, the manufacturers steer you to their self-pay prices instead (route 4), which start at $149 a month for a pill (the Wegovy pill or Foundayo) and $299 for an injection. Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect; Oct 26, 2026 · novocare.com

Medicare and Medicaid enrollees generally can't use manufacturer savings cards. Cash-pay program eligibility varies by manufacturer — check the current terms. Card terms: Zepbound, Wegovy (NovoCare).

The cheapest cash route and the least certain: $828 to $4,788 over a year at the providers listed here, with no FDA approval and no trial result of its own. Prices by provider, first month against later months, and the legal position: compounded semaglutide and tirzepatide price. Price checked Oct 26, 2026 · joinem.co; Oct 26, 2026 · medgm.org

The lowest posted price for each drug, in the order this site ranks them (price, not commission):

• Compounded tirzepatide, HealthRXHealthRX: $201 a month on a 3-month plan (billed $602 every 3 months), $2,609 for 52 weeks of medication. Last known price, Oct 17, 2026 — may have changed · confirm on HealthRX
• Compounded semaglutide, HealthRXHealthRX: $125 a month on a 3-month plan (billed $374 every 3 months), $1,621 for 52 weeks of medication. Last known price, Oct 17, 2026 — may have changed · confirm on HealthRX
• Compounded tirzepatide, EmbodyEmbody: on a one-year plan $119 a month, $1,428 billed upfront, non-refundable. Price checked Oct 26, 2026 · joinem.co
• Compounded semaglutide, EmbodyEmbody: on a one-year plan $69 a month, $828 billed upfront, non-refundable. Price checked Oct 26, 2026 · joinem.co

"From" prices are the lowest dose and usually rise as you titrate up. Each price shows the date it was last confirmed.

The most expensive route and the most certain: Wegovy pens are $349 a month through NovoCare Pharmacy and Zepbound vials $299–449 through LillyDirect, the FDA-approved drugs the trials tested, with no insurer decision to interrupt them (and nothing counted toward your deductible). Every dose, one-year totals and cost per pound: Wegovy and Zepbound cost by route. Price checked Oct 26, 2026 · novocare.com; Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect

Enter your starting weight, then answer the insurance question: the table reorders itself for your case. Every route with its explanation, no input needed, is on GLP-1 cost by route.

Federal law still bars Medicare Part D from covering drugs for weight loss, and the savings cards are closed to you, but the temporary Medicare GLP-1 Bridge gives eligible Part D enrollees Wegovy, Zepbound KwikPen or Foundayo for a $50 monthly copay. Who qualifies, the dates and the vial exclusion are on who qualifies for the Medicare GLP-1 Bridge; if the Bridge turned you down because of sleep apnea, read what to do when the Bridge denies you over sleep apnea. Medicaid coverage of GLP-1s for weight loss varies by state; the coverage router on the home page shows your state's status. Price checked Oct 25, 2026 · medicare.gov

Read the denial letter first, then work down the routes above: fix the paperwork (a complete prior authorization, a peer-to-peer review, an internal appeal within 180 days), ask whether Zepbound is on your plan's list instead, use the Wegovy savings card if you have commercial coverage (as little as $25 a month), and if the plan excludes weight-loss drugs outright, pay cash through NovoCare Pharmacy at $349 a month for the pens. Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect; Oct 26, 2026 · novocare.com

One exclusion is not always final: Wegovy is also FDA-approved to lower cardiovascular risk in adults with established heart disease and excess weight, so a prior authorization filed under that use, with the cardiac history attached, is reviewed against different criteria. Compounded semaglutide from $69 a month on a one-year plan (billed $828/yr upfront, non-refundable), or $79 a month for the first 4 weeks is cheaper still, but it has no FDA approval; see compounded semaglutide price and legal status. Price checked Oct 26, 2026 · joinem.co · joinem.co page 2

The same four routes, with Zepbound numbers: appeal or resubmit the prior authorization with dated weight records, check whether Wegovy is the plan's preferred drug, use the Zepbound savings card on commercial coverage, or buy it without insurance through LillyDirect from $299 a month for the 2.5 mg starting dose (Zepbound cost by dose). Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect

If you have moderate-to-severe obstructive sleep apnea, ask the prescriber to file for that use: Zepbound is FDA-approved for it in adults with obesity, and a plan that excludes weight-management drugs may still cover a sleep-apnea treatment once the sleep study is attached. On Medicare, read what to do when the Bridge denies you over sleep apnea.

Find the denial reason, give route 1 one properly documented try if your plan has no written exclusion, and price the cash routes for your own weight while you wait. The numbers on this page use trial averages at 230 lb; yours will differ.

Work out my own cost per pound →

Also useful: write your appeal letter · every route side by side · three questions to pick a provider · do I qualify for a GLP-1?

Mounjaro and Ozempic are FDA-approved for type 2 diabetes, not for weight management, so a plan usually denies them when the prescription is for weight loss. If you have type 2 diabetes, appeal with the diagnosis and your A1C records attached: that is the use the drugs are approved for. If you don't, ask your prescriber about the weight-management version of the same medicine, Zepbound (tirzepatide, like Mounjaro) or Wegovy (semaglutide, like Ozempic); it needs its own approval from the plan, and the routes above apply to it.

The deadline printed on your denial letter is the one that applies. Under federal rules, job-based and ACA Marketplace plans must give you at least 180 days after you receive the denial to file an internal appeal. Medicare Part D gives you 65 days from the date on the plan's notice to ask for a redetermination, and a Medicaid managed care plan 60 days from its notice. The appeal builder above works out the date from your letter.

If your job-based or Marketplace plan upholds the denial after the internal appeal, you can usually ask for an external review: an independent reviewer outside the insurance company decides, and the plan must accept the decision. You ask within four months of the final denial; a standard review is decided within 45 days and an urgent one within 72 hours. External review covers decisions that involve medical judgment, such as medical necessity; ask the plan or your state's consumer assistance program whether a plan exclusion can go to external review.

You can, but it rarely works: the plan is applying its written terms. Ask HR or the benefits team whether an exception or rider exists, ask your prescriber whether another FDA-approved use applies to you (Wegovy for established cardiovascular disease, Zepbound for obstructive sleep apnea), and price the cash routes. The appeal builder writes the exception request and the email to HR, and marks the request as low odds.

Part D cannot cover a drug used only for weight loss, so an appeal for weight management alone will not succeed; the GLP-1 Bridge is the route for that. For another approved use, such as Wegovy to lower cardiovascular risk or Zepbound for sleep apnea, a denial goes through Medicare's drug appeal levels: a redetermination by your plan, asked for within 65 days of the notice, then a reconsideration by the Independent Review Entity, then a hearing before an administrative law judge, the Medicare Appeals Council and federal court. A Medicare Advantage plan with drug coverage counts as a Part D sponsor under the rules, so the same steps apply.

No. The letters are put together by a script running in your browser, and the page makes no request with what you type: the denial wording, your name, health details, plan and reference number are not sent to us or anyone else, not saved in your browser and not put in the page address. Download .txt makes the file in your browser. We count only fixed events, such as that a letter was made and which of the six denial reasons was picked.

• Appeal rights and deadlines: HealthCare.gov, internal appeals and external review; job-based plans, 29 CFR 2560.503-1; Marketplace plans, 45 CFR 147.136; Medicare Part D, Medicare.gov, drug plan appeals and 42 CFR part 423, subpart M (Medicare Advantage drug plans: 42 CFR 423.4); weight-loss exclusion, 42 U.S.C. 1395w-102(e)(2)(A); Part D coverage of Wegovy for cardiovascular risk and Zepbound for sleep apnea, CMS; Medicaid, 42 CFR 438.402 and 438.408. Every rule the appeal builder quotes, with its source and the date we last checked it: appeal-rules.json.
• Approved uses: the FDA prescribing information for Wegovy, Zepbound, Mounjaro and Ozempic on DailyMed, read 2026-10-13.
• Employer coverage: KFF, 2025 Employer Health Benefits Survey: 19% of firms with 200 or more workers, and 43% of firms with 5,000 or more, cover GLP-1s used primarily for weight loss.
• Savings-card eligibility: Lilly, Zepbound coverage and savings; Novo Nordisk, Wegovy cost, coverage and savings, both read 2026-09-20. Medicare and Medicaid enrollees generally excluded.
• Medicare: CMS, BALANCE model and Medicare GLP-1 Bridge; KFF, what to know about the BALANCE model and the GLP-1 Bridge.
• Prices: the same single price file as the rest of the site; brand prices from Lilly and NovoCare, compounded prices from each provider's posted pricing. Each price shows the date it was last confirmed.
• Weight loss used for cost per pound (brand-name routes only; compounded products were not in these trials): 52-week trial means of 19% for tirzepatide 15 mg (SURMOUNT-1, NEJM 2022; −20.9% at 72 weeks) and 14% for semaglutide 2.4 mg (STEP 1, NEJM 2021; −14.9% at 68 weeks). Both trials paired the drug with diet and activity counselling, and individual results vary widely.